Chapter 1: Nomenclature of drugs

Chapter 2: Chemotherapy
Introduction
2.1.1 Alkylating antineoplastic agent
2.1.2 Nitrosoureas
2.2 Antimetabolites
2.3 Antitumor antibiotics
2.3.1 Anthracyclines
2.3.2 Non- Anthracyclines
2.4 Topoisomerase inhibitors
2.5 Mitotic inhibitors (Anti-microtubule Agents)
2.6 Corticosteroids
2.7 Other chemotherapy drugs
2.8 US FDA approved chemotherapy agents 
 2.9 Albumin-Bound Paclitaxel
2.10 Amifostine
2.11 Arsenic trioxide
2.12 Asparaginase Erwinia chrysanthemi
2.13 Azacitidine
2.14 Bendamustine
2.15 Bleomycin
2.16 Busulfan
2.17 Cabazitaxel 
2.18 Calaspargase Pegol-mknl
2.19 Capecitabine
2.20 Carboplatin
2.21 Carmustine
2.22 Chlorambucil
2.23 Cisplatin
2.24 Cladribine
2.25 Clofarabine
2.26 Cyclophosphamide
2.27 Cytarabine
2.28 Dacarbazine
2.29 Dactinomycin
2.30 Daunorubicin
2.31 Decitabine
2.32 Dexamethasone
2.33 Docetaxel
2.34 Doxorubicin
2.35 Doxorubicin Liposome
2.36 Epirubicin
2.37 Eribulin Mesylate
2.38 Etoposide
2.39 Fludarabine
2.40 5-Fluorouracil
2.41 Gemcitabine
2.42 Hydroxyurea
2.43 Idarubicin
2.44 Ifosfamide
2.45 Irinotecan
2.46 Ixabepilone
2.47 Lomustine
2.48 Lurbinectedin
2.49 Lutetium Lu 177-Dotatate
2.50 Mechlorethamine
2.51 Melphalan
2.52 Mercaptopurine
2.53 Methotrexate
2.54 Mitomycin-C
2.55 Mitoxantrone
2.56 Nelarabine
2.57 Oxaliplatin
2.58 Paclitaxel
2.59 Pemetrexed
2.60 Pralatrexate
2.61 Procarbazine
2.62 Radium 223 Dichloride
2.63 Temozolomide
2.64 Thioguanine
2.65 Thiotepa
2.66 Topotecan
2.67 Trabectedin
2.68 Valrubicin
2.69 Vinblastine
2.70 Vincristine
2.71 Vinorelbine
References

Chapter 3: Hormonal Therapy
Introduction
3.1 Abiraterone acetate
3.2 Anastrozole
3.3 Apalutamide
3.4 Bicalutamide
3.5 Darolutamide
3.6 Degarelix
3.7 Enzalutamide
3.8 Exemestane
3.9 Flutamide
3.10 Fulvestrant
3.11 Goserelin
3.12 Lanreotide
3.13 Letrozole
3.14 Leuprolide (Leuprorelin)
3.15 Megestrol acetate
3.16 Nilutamide
3.17 Raloxifene
3.18 Relugolix
3.19 Tamoxifen
3.20 Toremifene
References

Chapter 4: Targeted Therapy: Small Molecules
Introduction
4.1 Abemaciclib
4.2 Acalabrutinib
4.3 Afatinib
4.4 Alectinib
4.5 Alpelisib
4.6 Avapritinib
4.7 Axitinib
4.8 Belinostat
4.9 Bexarotene
4.10 Binimetinib
4.11 Bortezomib
4.12 Bosutinib
4.13 Brigatinib
4.14 Cabozantinib
4.15 Capmatinib
4.16 Carfilzomib
4.17 Ceritinib
4.18 Cobimetinib
4.19 Copanlisib
4.20 Crizotinib
4.21 Dabrafenib
4.22 Dacomitinib
4.23 Dasatinib
4.24 Duvelisib
4.25 Enasidenib
4.26 Encorafenib
4.27 Entrectinib
4.28 Erdafitinib
4.29 Erlotinib
4.30 Everolimus
4.31 Fedratinib
4.32 Fostamatinib
4.33 Gefitinib
4.34 Gilteritinib
4.35 Glasdegib
4.36 Ibrutinib
4.37 Idelalisib
4.38 Imatinib
4.39 Imiquimod
4.40 Infigratinib
4.41 Iobenguane I 131
4.42 Ivosidenib
4.43 Ixazomib
4.44 Lapatinib
4.45 Larotrectinib
4.46 Lenalidomide
4.47 Lenvatinib
4.48 Lorlatinib
4.49 Midostaurin
4.50 Mobocertinib
4.51 Neratinib
4.52 Nilotinib
4.53 Niraparib
4.54 Olaparib
4.55 Omacetaxine Mepesuccinate
4.56 Osimertinib
4.57 Palbociclib
4.58 Pazopanib
4.59 Pemigatinib
4.60 Pexidartinib
4.61 Pomalidomide
4.62 Ponatinib
4.63 Pralsetinib
4.64 Regorafenib
4.65 Ribociclib
4.66 Ripretinib
4.67 Romidepsin
4.68 Rucaparib
4.69 Selinexor
4.70 Selpercatinib
4.71 Selumetinib
4.72 Sonidegib
4.73 Sorafenib
4.74 Sunitinib
4.75 Talazoparib
4.76 Tazemetostat
4.77 Temsirolimus
4.78 Tepotinib
4.79 Thalidomide
4.80 Tivozanib
4.81 Trametinib
4.82 Tucatinib
4.83 Umbralisib
4.84 Vandetanib
4.85 Vemurafenib
4.86 Venetoclax
4.87 Vismodegib
4.88 Vorinostat
4.89 Zanubrutinib
4.90 Zoledronic Acid
References

Chapter 5: Targeted therapy: Monoclonal antibody
Introduction
5.1 Alemtuzumab
5.2 Bevacizumab
5.3 Cetuximab
5.4 Daratumumab
5.5 Ibritumomab Tiuxetan
5.6 Isatuximab-irfc
5.7 Margetuximab-cmkb
5.8 Naxitamab-gqgk
5.9 Necitumumab
5.10 Obinutuzumab
5.11 Ofatumumab
5.12 Panitumumab
5.13 Pertuzumab
5.14 Ramucirumab
5.15 Rituximab
5.16 Tafasitamab
5.17 Tagraxofusp
5.18 Trastuzumab
References

Chapter 6: Targeted Therapy: Antibody-drug conjugate (ADC)
Introduction
6.1 Ado-Trastuzumab Emtansine
6.2 Belantamab mafodotin-blmf
6.3 Brentuximab vedotin
6.4 Enfortumab Vedotin-ejfv
6.5 Fam-Trastuzumab Deruxtecan-nxki
6.6 Gemtuzumab Ozogamicin
6.7 Inotuzumab Ozogamicin
6.8 Loncastuximab tesirine- lpyl
6.9 Polatuzumab Vedotin-piiq
6.10 Sacituzumab Govitecan-hziy
6.11 Tisotumab Vedotin-tftv

Chapter 7: Immunotherapy
Introduction
7.1 Types of immunotherapies
7.1.1 Checkpoint inhibitors
7.1.2 T-cell transfer therapy/ Chimeric antigen receptor (CAR) T-cell therapy
7.1.3 Monoclonal antibodies
7.1.4 Immune system modulators
7.1.5 Treatment vaccines
7.2 Aldesleukin
7.3 Avelumab
7.4 Axicabtagene Ciloleucel
7.5 Blinatumomab
7.6 Brexucabtagene Autoleucel
7.7 Cemiplimab-rwlc
7.8 Denileukin Diftitox
7.9 Dinutuximab
7.10 Dostarlimab-gxly
7.11 Durvalumab
7.12 Elotuzumab
7.13 Idecabtagene Vicleucel
7.14 Ipilimumab
7.15 Lisocabtagene Maraleucel
7.16 Moxetumomab pasudotox- tdfk
7.17 Nivolumab
7.18 Pembrolizumab
7.19 Sipuleucel-T
7.20 Talimogene Laherparepvec
7.21 Tisagenlecleucel
References

Appendix
Table 1: A-Z list of cancer medicines (antineoplastics)
Table 2: Small molecules targeted drugs for cancer
Table 3: Monoclonal antibody as a targeted therapy
Table 4: Antibody-drug conjugate as a targeted therapy
Table 5: Immunotherapy agent